Ankara

The trials here

What the 14 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Head and neck cancer2 trials
• Hepatitis B2 trials
• Multiple myeloma2 trials
• Asthma1 trial
• Colorectal cancer1 trial
• Endometrial cancer1 trial
• Fatty liver disease (MASLD/MASH)1 trial

Phase

• Phase 311 trials
• Phase 23 trials

Status

• Active, not recruiting5 trials
• Completed5 trials
• Recruiting4 trials

Lead sponsor

• GlaxoSmithKline13 trials
• Tesaro, Inc.1 trial

Running trials

• Recruiting

  A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]

  NCT07099898· Phase 3· GlaxoSmithKline· Source

  Contact: Ismail Erturk (principal investigator)

• Recruiting

  A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

  NCT06679101· Phase 3· GlaxoSmithKline· Source

  Contact: Ahmet Kursad Gunes (principal investigator)

• Active, not recruiting

  A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)

  NCT06472076· Phase 3· GlaxoSmithKline· Source

• Recruiting

  A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

  NCT06256588· Phase 3· GlaxoSmithKline· Source

  Contact: Musa Barış Aykan (principal investigator)

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

  NCT06062420· Phase 2· GlaxoSmithKline· Source

• Recruiting

  Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

  NCT05855200· Phase 3· GlaxoSmithKline· Source

  Contact: Nuri Karadurmus (principal investigator)

• Active, not recruiting

  A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

  NCT05565378· Phase 2· GlaxoSmithKline· Source

• Active, not recruiting

  Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

  NCT04484623· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer

  NCT03981796· Phase 3· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Colorectal cancer1 recruiting
• Head and neck cancer1 recruiting
• Lung cancer1 recruiting
• Multiple myeloma1 recruiting

Closed trials

• Completed

  Phase 2b Study of GSK4532990 in Adults With NASH

  NCT05583344· Phase 2· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

  NCT05630807· Phase 3· GlaxoSmithKline· Source

• Completed

  Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

  NCT05630820· Phase 3· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

  NCT05281523· Phase 3· GlaxoSmithKline· Source

• Completed

  Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-Small Cell Lung Cancer

  NCT04475939· Phase 3· GlaxoSmithKline· Source